Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
Alan Motta do CantoBarbara Michaela Reis da Silva MarcelinoJuliana Lucena SchusselBruna F WastnerLaurindo Moacir SassiLuciana CorrêaRonaldo Rodrigues de FreitasBengt HasséusGöran KjellerCelso Augusto Lemos JuniorPaulo Henrique Braz-SilvaPublished in: Clinical oral investigations (2018)
The association between clinical-pathologic features and BRAF V600E mutation in ameloblastomas may provide directions for the treatment of this neoplasia. The use of BRAF inhibitors for targeted therapy could lead to an establishment of an alternative compared to the resective surgery.